"Ozempic breath" is boosting Hershey's sales of mints and gum

Hershey said GLP-1 adoption is boosting demand for gum and mints, with Ice Breakers sales up 8% over the quarter. While appetite-suppressing drugs may weigh on snack portions, the company is benefiting from increased demand for breath fresheners tied to side effects such as halitosis and burping. The news is supportive for Hershey's category mix, but the broader market impact is likely limited.

Analysis

This is less a consumer “health halo” story than a mix-shift story inside snack budgets: GLP-1 users are reducing calorie-dense impulse purchases but reallocating a sliver of spending toward small-format, repeat-buy functional products. That matters because mints and gum carry better turns, lower shrink, and often superior gross margin stability versus chocolate and center-store candy, so even modest mix improvement can support earnings quality more than headline revenue suggests.

The second-order effect is competitive: if Hershey is seeing the first measurable benefit, the real winners are likely the brands with the most habitual, low-ticket purchase patterns and strongest convenience-channel placement. That puts pressure on smaller confectionery peers that depend on indulgent snacking occasions, while retailers may see a category-level basket effect where GLP-1 households spend less per trip but visit more often for “mouth-freshening” top-ups.

For NVO, the market is still underpricing the downstream consumer rerouting effect. GLP-1 adoption doesn’t just reduce food volume; it changes the composition of demand, favoring products that solve nausea, dry mouth, or breath concerns and penalizing calorically dense snacks. The trend is early, but the secular question is whether this becomes a durable “functional snack” substitution pattern over 12-24 months as penetration broadens beyond high-income early adopters.

The key risk is reversibility: if side-effect management improves, dosing intensity falls, or utilization pauses as reimbursement tightens, the ancillary demand lift could fade quickly. Near term, the signal is more useful for relative trades than for standalone long-duration fundamental calls, because the upside to HSY is incremental while the downside to broad snack baskets could persist if GLP-1 adoption keeps climbing.

Key Decisions for Investors

• Long HSY vs. a basket of indulgent snack names for 3-6 months; the thesis is margin-resilient mix shift rather than top-line acceleration, with limited downside if the signal is overstated.
• Add a tactical long in HSY on pullbacks, but size modestly: treat this as a 1-2 quarter earnings-quality tailwind, not a re-rating catalyst.
• Long NVO on 6-12 month horizon as the market continues to underwrite downstream behavioral changes from GLP-1 penetration; the consumer spillover strengthens the broader adoption narrative.
• Avoid or underweight highly discretionary confectionery/cookie names most exposed to calorie substitution; relative underperformance risk grows if GLP-1 usage continues to expand through year-end.
• Consider a pair: long HSY / short a basket of snack peers with weaker functional product exposure, targeting a 5-8% relative spread if GLP-1 adoption remains a support to convenience-channel replenishment.